In this free webinar, learn how the application of appropriate digital biomarkers can potentially reduce sample sizes and shorten timelines in neuroscience clinical studies when used within a holistic endpoint strategy. Attendees will see how wearable sensors and composite scores enable more consistent, reliable measures in movement disorder trials. The featured speakers will discuss how vocal biomarkers like speech latency offer scalable, objective measures for depression and schizophrenia. The speakers will also share how advanced brain imaging techniques are shaping regulatory-ready endpoints in multiple sclerosis (MS) and beyond.
TORONTO, June 24, 2025 /PRNewswire-PRWeb/ -- Learn how advances in eCOA, digital movement analysis and medical imaging methodologies are shaping the future of neuroscience drug development.
Digital biomarkers are transforming neuroscience trials — moving from exploratory tools to validated, impactful endpoints. In this webinar, the featured speakers will share real-world examples and case studies showing how the strategic use of digital biomarkers can improve study precision, reduce timelines and lower sample size requirements.
Register for this webinar to explore how integrated digital strategies can enhance data quality and decision-making across psychiatric, neurologic and neurodegenerative clinical trials. Key areas of focus will include:
- Evaluating the role of digital biomarkers in improving study efficiency and timeline management through comprehensive endpoint strategies
- Assessing the application of wearable sensors and composite scores to advance movement disorder assessments
- Examining vocal biomarkers such as speech latency for objective and scalable measures in psychiatric research
- Reviewing advancements in brain imaging methodologies that contribute to the development of regulatory-ready endpoints in multiple sclerosis and related conditions
Join experts from Clario, Todd Rudo, MD, EVP, Chief Medical Officer; Douglas Arnold, MD, Professor, Department of Neurology & Neurosurgery, McGill University, President and CEO, NeuroRx, Senior Advisor; Dr. Mark Opler, VP eCOA Neuroscience; and Kristen Sowalsky, PhD, DC, VP, Medical & Scientific Affairs, Precision Motion, for the live webinar on Tuesday, July 15, 2025, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Progressing Beyond Exploratory Endpoints: The Value of Digital Biomarkers in Neuroscience Clinical Studies.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com/
SOURCE Xtalks
Share this article